Dermatological Beauty

The Dermatological Beauty Division puts cutting-edge research, breakthrough innovations and education at the heart of its mission to support dermatologists in the management of skin issues and aesthetic needs, to enhance wellbeing and quality of life.

Thanks to the power of L’Oréal’s Research & Innovation, the Division has demonstrated its expertise in key scientific territories like hyperpigmentation, the exposome, or the microbiome with pioneering studies on skin prone to acne, rosacea and psoriasis. In the last three years, L’Oréal Dermatological Beauty has conducted 200 clinical studies and almost doubled its number of medical publications. This has enabled the Division to develop advanced dermatological solutions, see its brands among the top four most prescribed by dermatologists and conquer the top five in the total worldwide skincare market. La Roche-Posay reached the top three position, while CeraVe jumped to number five.

The launch of Mela B3 by La Roche-Posay demonstrates the effectiveness of this scientific approach. The brand conducted a global epidemiological study on pigmentary disorders to assess their impact on quality of life, covering 48,000 people across 34 countries. The Melasyl™ revolutionary molecule matches the efficacy of the dermatological gold standard in hyperpigmentation, while ensuring high tolerance. Launched in 40 countries, Mela B3 has met with immediate success, marking the brand’s best innovation to date.

The strong growth of the Dermatological Beauty Division is based on a winning strategy in mature markets as well as in emerging countries. In the United States, CeraVe consolidated its leading position in total skincare across all channels and further strengthened its position as the number one brand recommended by dermatologists, pediatricians, and now in pharmacies. Meanwhile, La Roche-Posay pursued its exceptional performance, being the biggest contributor to total dermatological market growth. In China, the Division is outperforming the market driven by the continuing acceleration of SkinCeuticals and the rollout of CeraVe. Europe, the Division’s original market, achieved another great year of double-digit growth.

Emerging markets represent major growth drivers for two reasons: the increase in middle class consumers, as well as climatic conditions and growing urbanisation, which have a significant impact on skin health. The Dermatological Beauty Division recorded notable performances in both Sub-Saharan Africa and in India with the successful launch of CeraVe in Mumbai and Delhi. Building on this success, the Division is ready for further expansion in India, where dermocosmetics is one of the fastest growing beauty categories.

With the launch of the L’Oréal Universal Dermatology of all Colors, the Dermatological Beauty Division is putting the spotlight on diversity and inclusion in dermatology to ensure access to the right skincare for all skin types. Most of the world’s population has darkly pigmented skin, yet dermatological training remains largely focused on lightly pigmented skin. According to studies, only 15% of medical textbook cases show skin of colour. This can lead to misdiagnosis and inappropriate care and skincare routines.

The L’Oréal Universal Dermatology of all Colors focuses on three main areas: research, education and innovation. The Division has demonstrated its commitment to inclusive innovation through recent launches: La Roche-Posay’s UVMune 400 and Mela B3 were tested and developed to offer sun protection and hyperpigmentation care for all skin types; Vichy’s Dercos shampoo has proven to be effective for all hair types and skin colours. C E Ferulic from SkinCeuticals was tested and proven to correct seven signs of aging on all six Fitzpatrick skin types. The brand partnered with physicians to publish an algorithm that provides guidelines on integrating skincare pre- and post-procedures to optimise the results and reduce the side effects of aesthetic treatments for skin of colour patients.

One in four people live with skin problems. At L’Oréal, we believe that skin health should be a right because it directly impacts wellbeing and social inclusion. At the 2024 Skin Alliance Forum for the global dermatological community, the Dermatological Beauty Division launched L’Oréal Act for Dermatology, a five-year, €20-million investment programme aimed at funding access to skin health worldwide.

The programme focuses on four key areas: knowledge, advocacy, education and promoting skin health solutions. In 2024, to further boost knowledge, L’Oréal launched the Global Access to Skin Health Observatory in partnership with the ILDS. This is the first benchmark study of 194 countries investigating the distribution of dermatologists, patient barriers to dermatological care and access to ‘surrogate’ providers in dermatological deserts.

In terms of advocacy and education, the programme will raise awareness about skin health as a public health issue and support healthcare professionals through grants and training, including a €2-million investment for free access to key scientific publications.